October 2006
Edited
by:
Dennis Scott BVSc MACVSc
Ethical
Agents Ltd 54 Hobill Ave Wiri PO Box 97-110
SAMC
Ph 09-262-1388
Fax 09-262-1411 Freephone
0800 800-624
email eage@xtra.co.nz website
www.ethicalagents.co.nz
Inside this issue:
The fanfare of COX-2 specificity came in with all the fanfare of the war in Iraq. Although now much discredited in the human medical world veterinary companies do not seem to have understood the message and still push the barrow.
To say COX-2 specificity means greater safety is a bit like saying Baghdad is now a safer place since the invasion.
Pharmacological theory does not replace clinical trials or clinical experience, especially when safety is involved.
Basic pharmacological principles should mean cognizance of therapeutic
window and simple kinetics. In plain terms how much of the drug can we get to the site of action to be effective while at the same time causing no toxicity.
NSAID potency thus is a major factor, and COX-2 specific drugs do not have a more potent anti-inflammatory action.
The other large draw back with COX-2 specificity is that inflammation is multifactorial and drugs developed along a narrow mode of action can be less effective.
Extrapolating data across species, in particular human to dogs, is also fraught with problems .
.NSAIDs specific for COX-2 in humans have been found to be totally different in animals.
Human medical research is being very cautious about this issue and it is apparent that pure specificity is not desirable. COX-1 sparing may be preferable to specificity or non-selectivity.
* Lipoxygenase, the forgotten pathway
* The fallacy of COX 2 selectivity and safety
* Hemoplex, new uses for a quality product
* Plenty of jokes!!
A new release from Vétoquinol offers cost effective pain relief for large dogs.
The major problem is cost of therapy and the advent of the extremely convenient 120 mg
strength tablets of the COX 1 sparing NSAID Tolfedine has certainly overcome this problem.
Combining extremely strong pain relief and with high safety Tolfedine has a very
wide therapeutic window and a proven track record.
Tolfedine 120 mg shows, along with its stable mate Prilium, that Vétoquinol is aware cost is a major factor in treating large dogs.
